Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03989414
Title A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | GRC | FRA | ESP | DNK | DEU | CZE | CAN

Facility Status City State Zip Country Details
Local Institution - 119 Denver Colorado 80218 United States Details
Local Institution - 104 Tampa Florida 33612 United States Details
Local Institution - 108 Atlanta Georgia 30322 United States Details
Local Institution - 112 Chicago Illinois 60611 United States Details
Local Institution - 107 Chicago Illinois 60637 United States Details
Local Institution - 117 Boston Massachusetts 02114 United States Details
Local Institution - 101 Boston Massachusetts 02115 United States Details
Local Institution - 118 Boston Massachusetts 02215 United States Details
Local Institution - 113 Detroit Michigan 48201 United States Details
Local Institution - 106 Rochester Minnesota 55905 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Local Institution - 110 Winston-Salem North Carolina 27157 United States Details
Local Institution - 115 Columbus Ohio 43210 United States Details
Local Institution - 114 Nashville Tennessee 37203 United States Details
Local Institution - 116 Houston Texas 77030 United States Details
Swedish Cancer Institute Seattle Washington 98104 United States Details
Local Institution - 201 Calgary Alberta T2N 4N2 Canada Details
Local Institution - 205 Edmonton Alberta T6G 2G3 Canada Details
Local Institution - 204 Halifax Nova Scotia B3H 1V7 Canada Details
Local Institution - 203 Toronto Ontario M5G 2M9 Canada Details
Local Institution - 202 Montreal Quebec H1T 2M4 Canada Details
Local Institution - 802 Brno 625 00 Czechia Details
Local Institution - 801 Ostrava-Poruba 708 52 Czechia Details
Local Institution - 803 Praha 2 128 08 Czechia Details
Local Institution - 902 Odense 5000 Denmark Details
Local Institution - 903 Vejle 7100 Denmark Details
Local Institution - 703 Lille cedex 59037 France Details
Local Institution - 705 Marseille cedex 13273 France Details
Local Institution - 704 Nantes Cedex 01 44093 France Details
Local Institution - 701 Toulouse Cedex 9 31059 France Details
Local Institution - 702 Tours cedex 37044 France Details
Local Institution - 604 Freiburg 79106 Germany Details
Local Institution - 605 Hamburg 20246 Germany Details
Local Institution - 601 Heidelberg 69120 Germany Details
Local Institution - 602 Munchen 81675 Germany Details
Local Institution - 603 Wuerzburg 97080 Germany Details
Local Institution - 301 Athens 115 28 Greece Details
Local Institution - 404 Brescia 25123 Italy Details
Local Institution - 401 Milan 20133 Italy Details
Local Institution - 403 Reggio Emilia 42100 Italy Details
Local Institution - 402 Torino 10126 Italy Details
Local Institution - 504 Badalona 08916 Spain Details
Local Institution - 508 Madrid 28022 Spain Details
Local Institution - 501 Madrid 28041 Spain Details
Local Institution - 506 Malaga 29010 Spain Details
Local Institution - 505 Pamplona 31008 Spain Details
Local Institution - 502 Salamanca 37007 Spain Details
Local Institution - 503 Santander 39008 Spain Details
Local Institution - 507 Valencia 46026 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field